Product Information
RETACRIT 10,000 UNIT/ML VIAL is a brand biologic product labeled by Pfizer Inc., priced at $109.9774 per ML under NDC 00069130810. Its NADAC has been published 110 times since May 22, 2024.
Strength
10000 [iU]/mL
Manufacturer
Pfizer Inc.NDC
00069130810
Classification
Brand Biologic
Dosage Form
INJECTION, SOLUTION
Route
INTRAVENOUS; SUBCUTANEOUS
Last Updated
1/1/2026
Active Ingredients
EPOETINApproval Type
Biologic (BLA)
FDA Application
BLA125545On Market Since
6/18/2018
Pharmacological Classes
Price Statistics
The NADAC for RETACRIT 10,000 UNIT/ML VIAL has been published 110 times since May 22, 2024, and over the history we have for it it has risen 2.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $109.9774 per ML |
|---|---|
| All-time high | $109.9774 (Jun 24, 2026) |
| All-time low | $107.0245 (Sep 17, 2025) |
| 52-week high | $109.9774 |
| 52-week low | $107.0245 |
| Median price | $107.5980 |
| Average price | $108.0358 |
| Largest weekly change | +2.5% (Dec 31, 2025) |
| Weeks tracked | 110 |
| Tracking since | May 22, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient, strength, and dosage form. Compare the broader picture on the epoetin alfa-epbx market page.
Lowest-Cost Alternatives
No alternatives available
Frequently asked questions
What is the NADAC price of RETACRIT 10,000 UNIT/ML VIAL?
The current National Average Drug Acquisition Cost (NADAC) for RETACRIT 10,000 UNIT/ML VIAL, manufactured by Pfizer Inc., is $109.9774 per ML (NDC 00069130810), effective Jun 24, 2026.
How has the price of RETACRIT 10,000 UNIT/ML VIAL changed over time?
Over the history we have for it, the NADAC for RETACRIT 10,000 UNIT/ML VIAL has risen 2.2%. It has been tracked across 110 weekly CMS publications since May 22, 2024.
What are the highest and lowest recorded NADAC prices for RETACRIT 10,000 UNIT/ML VIAL?
Since May 22, 2024, the NADAC for RETACRIT 10,000 UNIT/ML VIAL has ranged from a low of $107.0245 (Sep 17, 2025) to a high of $109.9774 (Jun 24, 2026), with a median of $107.5980 per ML.
Are there cheaper alternatives to RETACRIT 10,000 UNIT/ML VIAL?
No other NADAC-published product currently shares the active ingredient, strength, and dosage form of RETACRIT 10,000 UNIT/ML VIAL, so no direct lower-cost alternative is listed.
Who manufactures RETACRIT 10,000 UNIT/ML VIAL?
RETACRIT 10,000 UNIT/ML VIAL (NDC 00069130810) is labeled by Pfizer Inc., and CMS classifies it as a brand biologic product.
Related Drugs
Same classification